Am­gen clos­es $28B Hori­zon ac­qui­si­tion a month af­ter FTC bat­tle end­ed

Am­gen has sealed its high-pro­file $27.8 bil­lion pur­suit of Hori­zon Ther­a­peu­tics, clos­ing the deal af­ter a lengthy 10-month ac­qui­si­tion process in which the Fed­er­al Trade Com­mis­sion at­tempt­ed to block the deal be­fore ul­ti­mate­ly reneg­ing last month, al­beit with some con­di­tions.

While an­a­lysts ini­tial­ly thought the law­suit would be “one of the weak­est re­cent cas­es” they’d seen from the FTC, the threat alone caused an in­dus­try up­roar and mul­ti­ple com­pa­nies have now band­ed to­geth­er to form the Part­ner­ship for the US Life Sci­ence Ecosys­tem to tout the in­no­va­tion that they say re­sults from M&A.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER